stockrow
Saturday 7 November 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
3.88
0.27
+7.48%
Follow ACRS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (55.51%) | (59.10%) | (48.42%) | (50.20%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
— | 4 | 3 | 3 | |
| (40.66%) | (41.07%) | (35.11%) | (34.10%) | ||
ROIC |
(107.72%) | (163.35%) | (131.57%) | (387.11%) | |
Return on Tangible Assets |
(79.93%) | (107.91%) | (83.32%) | (94.87%) | |
Average Days of Receivables |
0.00 | 275.74 | 210.00 | 259.55 | |
Free Cash Flow per Share |
(0.50) | (0.44) | (0.41) | (0.39) | |
Free Cash Flow |
(75.31) | (62.18) | (52.29) | (47.22) | |
Capital Expenditures |
(0.11) | (0.12) | (0.08) | (0.11) | |
| Other line items | |||||
Cash ROIC |
(26.79%) | (28.77%) | (20.99%) | (24.36%) | |
Accounts Receivable Turnover |
0.00 | 2.57 | 3.30 | 0.87 | |
Accounts Payable Turnover |
0.00 | 0.59 | 0.72 | 0.82 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 791.08 | 711.60 | 659.35 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,036.92% | 770.59% | 677.88% | 672.69% | |
Selling, General and Administrative Expense of Revenue |
381.27% | 282.74% | 269.82% | 280.76% | |
Share Based Compensation of Revenue |
184.58% | 141.82% | 143.98% | 158.24% | |
Operating CF/Net income |
0.94 | 0.82 | 0.75 | 0.73 | |
Depreciation/Fixed assets |
0.66 | 0.63 | 0.57 | 0.60 | |
Capex/Depreciation |
(0.26) | (0.28) | (0.19) | (0.24) | |
Revenue per Share |
0.04 | 0.06 | 0.07 | 0.06 | |
Operating CF per Share |
(0.50) | (0.43) | (0.41) | (0.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026